/PRNewswire/ Inhalon Biopharma, Inc., a clinical-stage immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating acute.
/PRNewswire/ Inhalon Biopharma, a start-up immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating a variety of acute.
Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled Muco-trapping Antibody for the Treatment of COVID-19 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
FORT WORTH, Texas, Dec. 22, 2020 /PRNewswire/
eTrueNorth the U.S.-based healthcare technology company that enables laboratory testing at retail pharmacies and enables all surge drive-through COVID-19 specimen collection sites, is partnering with the U.S. Department of Health and Human Services (HHS), the University of Wisconsin, Philips and BioIntelliSense Inc. under a US Army Medical Research Development Command (USAMRDC) funded award through the Medical Technology Enterprise Consortium (MTEC) to validate BioIntelliSense s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms. This clinical trial is evaluating the use of wearable diagnostics for early identification and containment of COVID-19 cases.